Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV ...

Belzutifan plus cabozantinib maintained durable antitumor activity in advanced clear cell renal cell carcinoma, per phase 3 ...

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell ...

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...

Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...

All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a ...

After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to ...

In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.